Emily A Scott, Aparna Balasubramanian, John Henry Brems, Tianshi David Wu, Michelle N Eakin, Scott L Zeger, Meredith C McCormack
{"title":"外周血嗜酸性粒细胞计数作为急性护理环境中哮喘加重严重程度的生物标志物。","authors":"Emily A Scott, Aparna Balasubramanian, John Henry Brems, Tianshi David Wu, Michelle N Eakin, Scott L Zeger, Meredith C McCormack","doi":"10.1016/j.anai.2025.04.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic asthma is associated with frequent exacerbations, but the relevance of peripheral eosinophil count at the time of exacerbation is unknown.</p><p><strong>Objective: </strong>To evaluate peripheral eosinophil count during an exacerbation requiring health care utilization and its associations with exacerbation course in adults with asthma.</p><p><strong>Methods: </strong>Adult asthma exacerbations between 2016 and 2023 which resulted in an emergency department visit or hospitalization were identified by International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes in the Johns Hopkins Asthma Precision Medicine Center of Excellence data repository. Outcomes included probability of admission, maximal level of care, length of stay, and discharge rate. We estimated associations between outcomes and eosinophil count using generalized estimating equations and generalized linear models.</p><p><strong>Results: </strong>Among 11,178 asthma exacerbations, 63% had peripheral eosinophil count measured during the encounter before steroid administration, and eosinophilia (≥150 cells/µL) was present in 61% of these. Risk of admission was nonlinearly associated with eosinophil count; exacerbations with eosinophil count of 150 to 300 cells/µL at presentation were least likely to result in admission, whereas those with 30 (odds ratio: 1.39, 95% CI: 1.26-1.54, P < .001) or 1000 cells/µL (odds ratio: 1.55, 95% CI: 1.35-1.79, P < .001) had higher odds of admission. Among inpatient exacerbations (N = 3825), encounters with eosinophil count more than or equal to 300 cells/µL had shorter median length of stay (3.1 vs 2.4 days, P < .001) and higher discharge rate (hazard ratio: 1.34, 95% CI: 1.22-1.48, P < .001) than those without eosinophilia (<150 cells/µL).</p><p><strong>Conclusion: </strong>Peripheral eosinophil count is a biomarker for asthma exacerbation severity and duration, offering opportunities for improved assessment and management of asthma exacerbations in acute care settings.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peripheral eosinophil count as a biomarker for asthma exacerbation severity in acute care settings.\",\"authors\":\"Emily A Scott, Aparna Balasubramanian, John Henry Brems, Tianshi David Wu, Michelle N Eakin, Scott L Zeger, Meredith C McCormack\",\"doi\":\"10.1016/j.anai.2025.04.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Eosinophilic asthma is associated with frequent exacerbations, but the relevance of peripheral eosinophil count at the time of exacerbation is unknown.</p><p><strong>Objective: </strong>To evaluate peripheral eosinophil count during an exacerbation requiring health care utilization and its associations with exacerbation course in adults with asthma.</p><p><strong>Methods: </strong>Adult asthma exacerbations between 2016 and 2023 which resulted in an emergency department visit or hospitalization were identified by International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes in the Johns Hopkins Asthma Precision Medicine Center of Excellence data repository. Outcomes included probability of admission, maximal level of care, length of stay, and discharge rate. We estimated associations between outcomes and eosinophil count using generalized estimating equations and generalized linear models.</p><p><strong>Results: </strong>Among 11,178 asthma exacerbations, 63% had peripheral eosinophil count measured during the encounter before steroid administration, and eosinophilia (≥150 cells/µL) was present in 61% of these. Risk of admission was nonlinearly associated with eosinophil count; exacerbations with eosinophil count of 150 to 300 cells/µL at presentation were least likely to result in admission, whereas those with 30 (odds ratio: 1.39, 95% CI: 1.26-1.54, P < .001) or 1000 cells/µL (odds ratio: 1.55, 95% CI: 1.35-1.79, P < .001) had higher odds of admission. Among inpatient exacerbations (N = 3825), encounters with eosinophil count more than or equal to 300 cells/µL had shorter median length of stay (3.1 vs 2.4 days, P < .001) and higher discharge rate (hazard ratio: 1.34, 95% CI: 1.22-1.48, P < .001) than those without eosinophilia (<150 cells/µL).</p><p><strong>Conclusion: </strong>Peripheral eosinophil count is a biomarker for asthma exacerbation severity and duration, offering opportunities for improved assessment and management of asthma exacerbations in acute care settings.</p>\",\"PeriodicalId\":50773,\"journal\":{\"name\":\"Annals of Allergy Asthma & Immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2025-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Allergy Asthma & Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.anai.2025.04.005\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.anai.2025.04.005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Peripheral eosinophil count as a biomarker for asthma exacerbation severity in acute care settings.
Background: Eosinophilic asthma is associated with frequent exacerbations, but the relevance of peripheral eosinophil count at the time of exacerbation is unknown.
Objective: To evaluate peripheral eosinophil count during an exacerbation requiring health care utilization and its associations with exacerbation course in adults with asthma.
Methods: Adult asthma exacerbations between 2016 and 2023 which resulted in an emergency department visit or hospitalization were identified by International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes in the Johns Hopkins Asthma Precision Medicine Center of Excellence data repository. Outcomes included probability of admission, maximal level of care, length of stay, and discharge rate. We estimated associations between outcomes and eosinophil count using generalized estimating equations and generalized linear models.
Results: Among 11,178 asthma exacerbations, 63% had peripheral eosinophil count measured during the encounter before steroid administration, and eosinophilia (≥150 cells/µL) was present in 61% of these. Risk of admission was nonlinearly associated with eosinophil count; exacerbations with eosinophil count of 150 to 300 cells/µL at presentation were least likely to result in admission, whereas those with 30 (odds ratio: 1.39, 95% CI: 1.26-1.54, P < .001) or 1000 cells/µL (odds ratio: 1.55, 95% CI: 1.35-1.79, P < .001) had higher odds of admission. Among inpatient exacerbations (N = 3825), encounters with eosinophil count more than or equal to 300 cells/µL had shorter median length of stay (3.1 vs 2.4 days, P < .001) and higher discharge rate (hazard ratio: 1.34, 95% CI: 1.22-1.48, P < .001) than those without eosinophilia (<150 cells/µL).
Conclusion: Peripheral eosinophil count is a biomarker for asthma exacerbation severity and duration, offering opportunities for improved assessment and management of asthma exacerbations in acute care settings.
期刊介绍:
Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.